We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00453128
First Posted: March 28, 2007
Last Update Posted: March 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sociedade Galega de Reumatoloxía
  Purpose
The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.

Condition
Chondrocalcinosis

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Resource links provided by NLM:


Further study details as provided by Sociedade Galega de Reumatoloxía:

Estimated Enrollment: 240
Study Start Date: January 1997
Study Completion Date: December 2006
Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

  • Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00453128


Locations
Spain
Meixoeiro Hospital
Vigo, Pontevedra, Spain, 36214
Sponsors and Collaborators
Sociedade Galega de Reumatoloxía
Investigators
Principal Investigator: José M Pego-Reigosa, MD, PhD Meixoeiro Hospital, Vigo (Pontevedra) SPAIN
  More Information

ClinicalTrials.gov Identifier: NCT00453128     History of Changes
Other Study ID Numbers: SGR1
First Submitted: March 26, 2007
First Posted: March 28, 2007
Last Update Posted: March 28, 2007
Last Verified: March 2007

Keywords provided by Sociedade Galega de Reumatoloxía:
Calcium Pyrophosphate
associated conditions

Additional relevant MeSH terms:
Chondrocalcinosis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Calcium, Dietary
Bone Density Conservation Agents
Physiological Effects of Drugs